CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Onconic Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Onconic Therapeutics Inc
Phone: +82 234540780p:+82 234540780 SEOUL, 06236  South Korea Ticker: 476060476060
Business Summary
Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023-----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer JohnKim
Chief Financial Officer Jong KilShin
Chief Scientific Officer Hyun JuCha

General Information
Outstanding Shares: 10,803,960 (As of 12/19/2024)
Stock Exchange: KDQ
Fax Number: +82 234540784


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 30, 2024